Vera Therapeutics Inc (NASDAQ:VERA)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 1.03. At the close of trading, the stock’s price was $40.84, to imply an increase of 0.86% or $0.35 in intraday trading. The VERA share’s 52-week high remains $50.78, putting it -24.34% down since that peak but still an impressive 77.38% since price per share fell to its 52-week low of $9.24. The company has a valuation of $2.24B, with an average of 0.84 million shares in intraday trading volume over the past 10 days and average of 538.48K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Vera Therapeutics Inc (VERA), translating to a mean rating of 1.22. Of 5 analyst(s) looking at the stock, 0 analyst(s) give VERA a Sell rating. 1 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Vera Therapeutics Inc (NASDAQ:VERA) trade information
After registering a 0.86% upside in the last session, Vera Therapeutics Inc (VERA) has traded red over the past five days. The 5-day price performance for the stock is -5.99%, and 7.02% over 30 days. With these gigs, the year-to-date price performance is 165.54%. Short interest in Vera Therapeutics Inc (NASDAQ:VERA) saw shorts transact 6.46 million shares and set a 16.11 days time to cover.
The extremes give us $6 and $38 for target low and target high price respectively. As such, VERA has been trading 6.95% off suggested target high and 85.31% from its likely low.
Vera Therapeutics Inc (VERA) estimates and forecasts
Looking at statistics comparing Vera Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Vera Therapeutics Inc (VERA) shares are 8.85% up over the last 6 months, with its year-to-date growth rate lower than industry average at -14.22% against 17.60%.
VERA Dividends
Vera Therapeutics Inc has its next earnings report out on 2024-Aug-08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Vera Therapeutics Inc (NASDAQ:VERA)’s Major holders
Vera Therapeutics Inc insiders hold 7.85% of total outstanding shares, with institutional holders owning 108.34% of the shares at 117.56% float percentage. In total, 108.34% institutions holds shares in the company, led by AVORO CAPITAL ADVISORS LLC. As of 2024-06-30, the company held over 4.31 million shares (or 8.4548% of shares), all amounting to roughly $155.92 million.
The next major institution holding the largest number of shares is PRICE T ROWE ASSOCIATES INC /MD/ with 3.62 million shares, or about 7.1022% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $130.98 million.
We also have Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Vera Therapeutics Inc (VERA) shares. Going by data provided on Jun 30, 2024 , Price (T.Rowe) New Horizons Fund holds roughly 1.42 shares. This is just over 2.59% of the total shares, with a market valuation of $57.99 million. Data from the same date shows that the other fund manager holds a little less at 1.33, or 2.43% of the shares, all valued at about 54.37 million.
